AI Pathology Platform Achieves Full European Clearance for Breast Cancer Biomarker Suite

Ibex Medical Analytics has secured the final regulatory piece needed to offer European pathology laboratories a complete AI-powered breast cancer diagnostic solution. The company's recent IVDR certification for estrogen receptor (ER), progesterone receptor (PR), and Ki67 quantification tools completes a comprehensive suite that now spans all major breast cancer biomarkers on a single unified platform.

The certification marks a strategic milestone in the competitive digital pathology market, where Ibex now offers end-to-end coverage across hematoxylin and eosin (H&E), HER2, ER, PR, and Ki67 analysis through its Ibex 4 platform. This comprehensive approach contrasts with competitors offering point solutions for individual biomarkers, potentially creating operational advantages for laboratories seeking to standardize their AI-assisted workflows.

Clinical Validation Demonstrates Measurable Improvements

Multi-center validation studies underpinning the certification revealed tangible gains in diagnostic consistency. Ki67 interobserver agreement—a persistent challenge in breast pathology—improved by 10% when pathologists used AI assistance. The platform achieved 94% accuracy when compared against reference expert scores, suggesting meaningful potential to reduce the diagnostic variability that can affect treatment decisions.

The ER and PR quantification tools align with ASCO/CAP 2020 guidelines, while Ki67 analysis follows International Ki67 Working Group and St. Gallen expert consensus standards. Dr. Anne Vincent-Salomon, pathologist at Institut Curie and director of the Women's Cancer Institute, participated in the validation studies that supported the regulatory submission.

Notably, the platform's HER2 capabilities include cell-level quantification that enables identification of HER2-low and HER2-ultralow breast cancers—emerging categories that determine eligibility for newer targeted therapies. This granular classification capability addresses a clinical need that has intensified as treatment options for HER2-low patients have expanded.

Market Positioning and Adoption Considerations

For European pathology laboratories, the certification provides access to a regulatory-compliant, comprehensive solution that could standardize biomarker quantification across institutions. The unified workspace approach may appeal to laboratories seeking to reduce vendor complexity and streamline pathologist workflows across multiple stain types.

Yair Heller, CEO at Ibex Medical Analytics, emphasized the company's ongoing partnerships with laboratory information system and image management system vendors—integrations that will be critical to clinical adoption as laboratories evaluate whether to deploy comprehensive platforms or maintain best-of-breed point solution approaches.

The standardization potential extends beyond operational efficiency to clinical impact. Improved consistency in Ki67 scoring and precise HER2-low identification may reduce treatment misclassification and improve patient access to appropriate targeted therapies. As breast cancer treatment becomes increasingly personalized based on biomarker profiles, diagnostic precision in quantifying these markers directly influences therapeutic decision-making.

Sources

1. Ibex Earns European Certification for Complete Breast Pathology AI Suite — CLP Magazine